Literature DB >> 25467157

Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents.

Jun Zhu1, Lin He1, Liang Ma1, Zhe Wei1, Jiqiang He1, Zhuang Yang2, Yuzhi Pu1, Dong Cao1, Yuzhe Wu2, Mingli Xiang1, Aihua Peng1, Yuquan Wei1, Lijuan Chen3.   

Abstract

Thirty-one 4-oxoquinoline-3-carboxamides derivatives were synthesized and evaluated for their anti-fibrotic activities by the inhibition of TGF-β1-induced total collagen accumulation and anti-inflammatory activities by the inhibition of LPS-stimulated TNF-α production. Among them, three compounds (10a, 10l and 11g) exhibited potent inhibitory effects on both TGF-β1-induced total collagen accumulation and LPS-stimulated TNF-α production. Furthermore, oral administrations of 10l at a dose of 20 mg/kg/day for 4 weeks effectively alleviated lung inflammation and injury, and decreased lung collagen accumulation in bleomycin-induced pulmonary fibrosis model. Histopathological evaluation of lung tissue confirmed 10l as a potential, orally active agent for the treatment of pulmonary fibrosis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Oxoquinoline-3-carboxamides; Anti-inflammatory; Collagen accumulation; Pulmonary fibrosis; TGF-β1; TNF-α

Mesh:

Substances:

Year:  2014        PMID: 25467157     DOI: 10.1016/j.bmcl.2014.10.071

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Synthesis of Novel 2-(Pyridin-2-yl) Pyrimidine Derivatives and Study of Their Anti-Fibrosis Activity.

Authors:  Yi-Fei Gu; Yue Zhang; Feng-Li Yue; Shao-Tong Li; Zhuo-Qi Zhang; Jing Li; Xu Bai
Journal:  Molecules       Date:  2020-11-10       Impact factor: 4.411

2.  Synthesis, Biological Evaluation, and Molecular Modeling Studies of New 8-methyl-4-oxo-1,4-dihydroquinoline-3-carbohydrazides as Potential Anti-HIV Agents.

Authors:  Mehrdad Alemi; Fatemeh Kamali; Rouhollah Vahabpour Roudsari; Zahra Hajimahdi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2022-05-17       Impact factor: 1.962

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.